Infant Bacterial Therapeutics (IBT), a subsidiary of BioGaia, announced that the IND (Investigational New Drug) for the prevention of necrotizing enterocolitis (NEC), has been accepted by the FDA (U.S. Food and Drug Administration). Furthermore, IBT has received approval from the MPA (Medical Product Agency) to conduct its clinical trial in Sweden.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127.2 SEK | +0.08% | +3.58% | +25.69% |
05/06 | BioGaia AB Establishes Its Own Distribution in Australia and New Zealand | CI |
07/05 | Nordic Shares Closed Up Tuesday; Storskogen Group Series B Topped Leaders | DJ |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.69% | 121.83Cr | |
+8.54% | 10TCr | |
+11.97% | 4.39TCr | |
-11.76% | 3.32TCr | |
+79.34% | 2.94TCr | |
-12.20% | 1.61TCr | |
+4.00% | 1.47TCr | |
-1.90% | 1.29TCr | |
+178.17% | 1.05TCr | |
+1.80% | 882.97Cr |
- Stock Market
- Equities
- BIOG B Stock
- News BioGaia AB
- U.S. Food and Drug Administration Accepts BioGaia's IND for the Prevention of Necrotizing Enterocolitis and Receives Approval from the MPA to Conduct Its Clinical Trial in Sweden